In the following study, researchers investigated the effects of BP-1-102, a novel inhibitor of signal transducer and activator of transcription 3 (STAT3), on AGS cells. Flow cytometric analysis and Western blot analysis revealed that BP-1-102 induces apoptosis and inhibited the phosphorylation of STAT3 and its target genes in a time- and dose-dependent manner. These results indicate that BP-1-102 has the potential to be used as an antitumor agent in AGS cells through the modulation of STAT3 signaling pathways. [LINK]
AGS cells are derived from the gastric tissue of a 54-year-old female, and represent one of the major players in the field of genomics research in gastric cancer. The cells are suitable for preclinical xenografts , and are prime subjects for transfection experiments. AGS cells have been researched extensively for pharmaceutical applications of histone deacetylase inhibition in stalling the growth of gastric cancer. They can easily serve as recipients of transfected genomic material, such as siRNA, which can be used for library screenings and the development of gene therapies specific to gastric cancer.
Comments
Post a Comment